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Summary  
Objective: To investigate the effect of diacetyl rhein (DAR) on the synthesis, turnover and composition of cartilage 
in an experimental model of osteoarthritis n beagle bitches. 
Design: Osteoarthritis was induced in mature beagle bitches by the transection of the cranial cruciate ligament. Six 
animals received DAR 20 mg/kg daily for 11 weeks. A matched group received empty capsules daily for the same period. 
At 11 weeks, articular cartilage was examined for the ratio of the 6:4-sulfated isaccharides of chondroitin and the 
tissue concentration of hydroxyproline and glycosaminoglycan. In addition, labeling studies were performed to 
estimate the effect of DAR on proteoglycan synthesis and turnover. 
Results: DAR had no effect on body weight or food consumption but induced a mild diarrhea and slightly increased 
the incidence of vomiting. DAR tended to reduce proteoglycan synthesis, however, DAR did reduce proteoglycan 
turnover in the femoral cartilage. DAR produced changes in the composition of the osteoarthritic cartilage that could 
only partly be accounted for by changes in hydration and/or swelling. In addition, it was noted that induction of 
osteoarthritis ncreased the ratio of chondroitin 6-sulfated to chondroitin 4-sulfhted isaccharides; DAR reduced the 
ratio in tibial plateau cartilage from osteoarthritic joints compared with untreated tissue from osteoarthritic joints. 
DAR showed moderate reduction on the biosynthesis of proteoglycans. DAR also produced a reduction in proteoglycan 
turnover from all anatomical areas compared with non-treated controls in both the lateral and medial femoral condyles. 
Conclusions: DAR was well tolerated by the experimental nimals, but did not produce significant changes in the 
synthesis or turnover of proteoglycans. The slight reduction in proteoglycan synthesis may prove to be biologically 
significant after chronic dosing. DAR's effects on the hydroxyproline and g]ycosaminoglycan content suggest, however, 
that it must influence the swelling of cartilage and loss of glycosaminoglycan. This indicates that small changes can 
translate, to significant differences in cartilage composition over an l l-week time period. 
Keywords: Diacetylrhein, Osteoarthritis. 
I n t roduct ion  
OSTEOARTHRITIS is a disease that  affects many 
joints caus ing changes to all of the jo int  s t ructures  
par t icu lar ly  the cart i lage,  bone and capsule.  The 
disease is commonly  not  wel l -managed pharm- 
aceut ica l ly  [1], and those compounds  that  are 
commonly  used are analgesics  or nonstero ida l  
ant i - in f lammatory  agents  (NSA]Ds). Both ap- 
proaches  are pal l iat ive and are par t icu lar ly  
unsuccessful  in t reat ing  more  severe disease. 
Of more interest  recent ly,  are agents  that  have  
disease-modifying character is t ics  (DMARDs- -  
disease-modifying ant i - rheumat ic  drugs [1]) or that  
are chondroprotect ive  [2, 3], in that  they in some 
way prevent  cart i lage destruct ion or prevent  cell 
death. A l though there have  been many claims for 
disease-modifying act iv i ty  of var ious  agents,  few 
have been subjected to r igorous exper imenta l  
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invest igat ion or indeed cl inical  tr ia l  to assess 
disease modif icat ion.  
One agent,  d iacetyl  rhe in  [DAR; F igure  1 (a)l has 
a t t rac ted  par t i cu la r  a t tent ion  of ]ate [4]. The 
molecule is an anthraqu inone  which on adminis-  
t ra t ion  is complete ly  deacety lated to the s t ruc ture  
shown in F igure l(b), which is known as rhein.  
Rhein has a diverse pharmacology,  and is capab le  
of inh ib i t ing glucose uptake  [5, 6] prote in  synthes is  
['7], protease act iv i ty  [8] and var ious  other  
b iochemical  processes. As a result,  it has been 
suggested that  DAR may be useful as an 
ant i -cancer  agent.  What  is perhaps more  intr igu- 
ing is the abi l i ty of DAR to improve the symptoms 
of osteoarthr i t is ,  by (it is c la imed) disease 
modif icat ion, I t  bas been shown that  DAR does not 
work  in the same way as orthodox ant i - inf lamma- 
tory agents  [4, 9, ]0], yet can be shown in humans  
to produce rel ief  by about  2--3 weeks after  the 
commencement  of t reatment  [4, 11, ] 2]. 
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DAR significantly inhibited the histological 
development of lesions in animal models of 
osteoarthritis [13]. This has been demonstrated in 
spontaneous disease in the guinea-pig where no 
surgical or chemical agent has been used to 
initiate the disease process [14, 15]. It is not clear, 
however, how DAR exerts its anti-osteoarthritic 
effects. This study was intended to examine the 
effects of DAR on the early morphological and 
biochemical changes [16, 17] produced by the 
induction of osteoarthritis in a well-established 
surgical model. One of the approaches adopted in 
this study was to examine the effect of DAR on the 
production of mimotopes recognized by the 
monoclonal antibody 7-D-4. These mimotopes have 
been shown to be greatly elevated in osteoarthritic 
tissue [18,19]. We have supposed that such 
mimotopes may be related in some way to a repair 
mechanism that generally is ineffective. We 
proposed that successful drug intervention may 
have some effect on the expression of these 
glycosaminoglycan mimotopes. Eventually we 
might hope that the level of these mimotopes could 
be used to quantitate beneficial change due to drug 
treatment. It was hoped that a diverse approach 
such as this might allow investigation of the 
potential molecular events which DAR may 
modulate, and hence, give clues as to how future 
anti-osteoarthritic drugs should be designed. 
single suture. The dogs were housed singly in pens 
with low dividers, which reduced the frequency of 
the dogs rising on their back legs to see their 
kennel mates or handlers entering the room. 
Experience has shown that this reduces the 
severity of the arthritic lesions. Because DAR 
seems to be most effective in animal models in 
reducing the rate of progression of mild or 
moderate disease, it was intended to have as mild 
a lesion as possible to maximize the effect of the 
molecule. 
The animals in the DAR group received DAR at 
a dose of 20 mg/kg daily in capsule form, the first 
dose being administered the day after surgery. The 
control group received only empty capsules. The 
dogs were observed over the next 11 weeks for 
various indications (body weight, food consump- 
tion) and clinical signs (liquid faeces, colored 
urine, colored faeces, vomiting). Hematology and 
blood biochemistry were examined at weeks -2, 5 
and 10 from the commencement of dosing. All dogs 
were killed 11 weeks after surgery by a single 
lethal dose of sodium thiopentone. On receiving 
the joints, they were washed, doused with ethanol 
then each knee flexed :and opened under aseptic 
conditions. Excess so f t  tissue and muscle was 
removed before photography of the distal femurs. 
Full-thickness blocks (i.e. down to bone) were 
removed using scalpels and fixed in buffered 
formalin for light microscopy. Tissue removed for 
Mater ia l s  and methods  
EXPERIMENTAL ANIMALS 
Twelve beagle bitches, weighing between 10.5 
and 13.6kg were divided into two groups, one 
group received DAR (mean weight 12.2 kg, range 
10.9-13.6 kg) and the other received empty capsules 
as controls (mean weight 12.2kg, range 10.5- 
13.3 kg). The dogs were maintained for a 'predose' 
period of 4 weeks before surgery and dosing 
commenced to establish that the dogs had become 
acclimatized and that any abnormalities (blood 
chemistry, etc.) could be identified. This was 
necessary because the animals were brought in 
flcom a remote site and may not have settled in the 
new environment. During this period the animals 
received no medication. Following the predose 
period, all dogs were subjected to division of the 
cranial cruciate ligament by a blind incision 
[20-22]. The anterior cruciate ligament of the right 
leg was divided and the contralateral leg provided 
the control 'normal' tissue. Two dogs (970 and 966) 
in the DAR group bled significantly and required 
suturing. In the control group, only dog 978 
showed any significant bleeding, and required a 
(a) 0 0 





FIG. 1. (a) The structure of diacetyl rhein. (b). The 
structure of rhein, the totally deacetylated metabolite of
diacetyl rhein. 
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light microscopic examination were from the same 
sites used for the tissue culture experiments. 
PREPARATION, LABELING AND MAINTENANCE OF 
CARTILAGE CULTURES 
The cartilage was removed and prepared for 
explant culture essentially as outlined by Carney 
et al. [22J from the following anatomical sites: the 
medial tibial plateaux, both operated and control 
(MTP A, MTP N); the lateral tibial plateaux, both 
operated and control (LTP A, LTP N); the medial 
femoral condyles, both operated and control (MFC 
A, MFC N); the lateral femoral condyles, both 
operated and control (LFC N, LFC A); and the 
patellar grooves (intercondylar fossa), both oper- 
ated and control (PG A, PG N). The tissue was 
distributed into preweighed vials containing 
Dulbecco's modified Eagle's medium (DMEM) 
(containing 10% (v:v) fetal calf serum (FCS); 1 ml). 
After distribution, the slices were pulse labeled 
with a mixture of two radiotracers each at 
10 ~tCi/ml. The two isotopes used were '~SO~-, as 
inorganic Na2~'~SO~ and [:~H]-proline. In this study 
we have examined only the results from the 
sulfate incorporation experiments. The results of 
protein labeling studies will be given elsewhere. 
Pulse labeling was for 4h. Following pulse 
labeling, the tissue was washed (2xl  ml) with 
sterile PBS, then resuspended in DMEM contain- 
ing 10% FCS for a chase period of 48 h. All pulse 
and chase protocols were performed in an 
humidified incubator at 37°C gassed with COs/air 
(5/95%). The radioisotope was incorporated almost 
exclusively into sulfated glycosaminoglycans, and 
hence, will enable us to determine the fate of 
newly-synthesized proteoglycans. 
After pulse and chase protocols had been 
completed, the chase medium was removed and 
stored at -20°C. The tissue slices were extracted 
for 48 h with the following extractant: 4 M 
GuC1/50 mM acetate pH 5.8 containing the follow- 
ing protease inhibitors: 100 mM aminocaproic acid; 
10mM EDTA; 5raM benzamidine.HC1. When ex- 
traction was completed the guanidine was removed 
and stored at -20°C. The tissue slices were washed 
with water (2-3xl ml) and then digested with 
pepsin at 50 mg/ml in 0.5 M acetic acid (1 ml) for 
48 h at 4°C. The pepsin digest was then removed 
and stored as for all the previous amples and the 
tissue slices finally digested with papain (13 rag/ 
100 ml in 0.5 M acetate buffer pH 6.5 containing 
20 mM cysteine HC1 and 1 mM EDTA; 1 ml) for ] 6 h 
at 65°C. Chase samples and guanidine extracts 
were dialyzed exhaustively against deionized 
water. All samples were then counted in a liquid 
scinti l lation spectrometer. The complete removal 
of unicorporated isotope by dialysis was confirmed 
by chromatography on Sephadex G-25 of several 
random samples in each dialysis batch. The total 
counts in the chase medium, guanidine extract, 
pepsin digest and papain digest were determined. 
The total incorporation (pmoles SO4/mg cartilage/ 
h) could then be determined as could the rate of 
release of newly synthesized proteoglycan and/or 
protein into the medium over a 48-h period. This 
figure was determined by calculation of the 
percentage of the total incorporated counts found 
in the chase medium. 
IMMUNOSTAIN ING OF CARTILAGE SECTIONS 
USING 7-D-4 
Blocks of cartilage were removed from all of the 
areas of the joint and were fixed in 2.5% 
glutaraldehyde in 0.1 M phosphate buffer pH 7.4. 
The sample blocks were then embedded in lowicry] 
K4M resin at -35°C. Sections (0.5 ~m) were cut and 
collected on gelatin coated slides. The sections 
were stained using 7-D-4 at a dilution of ] in 50 in 
]% rabbit serum and were visualized using the 
Amersham DAB enhancement kit (cat. no. RPN 
1174). 
Following staining, the preparations were pho- 
tographed, taking care to use the same area in each 
preparation. The full-depth photographs were 
taken and a grid devised so that one could examine 
the amount of staining in four separate equal- 
depth zones from the articular surface to the 
subchondral bone. A scoring system was devised so 
that the degree of staining, where 0 indicated no 
staining and 4 virtually complete staining, in any 
area could be determined. A panel of 12 observers 
then scored the photographs individually in a 
double-blinded manner and the results were then 
decoded, collated and examined. 
ANALYTICAL METHODS 
Uronic acid was determined by the method of 
Bitter and Muir [23], which had been scaled down 
for microtiter plate analysis [24]. Hydroxyproline 
was estimated by the method of Stegemann and 
Stalder [25], again scaled down for microtiter plate 
analysis. Radioactivity was determined by liquid 
scintil lation spectroscopy, using a scinti l lant to 
sample ratio of >4. 
Analysis of the sulfate isomers of chondroitin 
was by capillary electrophoresis essentially as 
outlined by Carney and Osborne [26]. Electrophor- 
esis was performed on guanidinc extracts that had 
been subjected to chondroitinase digestion under 
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the following conditions. Samples were adjusted to 
0.01 M tris acetate pH7.3 by the addition of a 
concentrated stock buffer. Chondroit inase ABC 
(30 mU) was added and the samples incubated for 
1 h. The samples were then electrophoresed at
15 kV, 40°C in 40mM phosphate/40mM sodium 
dodecyl sulfate (SDS)/10 mM sodium tetraborate 
pH 9.0 using Applied Biosystems 270A and 270HT 
instruments. The capillary was monitored at 
232 nm and the areas under each isomer peak 
estimated by a SpectraPhysics SP4290 integrator. 
Throughout his study, statistical significance 
was assessed by a one-tailed Walsh test for paired 
data. This test was part icularly appropriate for the 
type of paired data generated in this investigation, 
which represents a large number of single 
observations and not multiple comparisons which 
would have benefitted from analysis of variance. 
Resu l ts  
GROSS ANATOMY 
At the time of death, all animals had large 
medial and lateral femoral osteophytes, as de- 
scribed previously. There were no carti lage lesions 
obvious on any of the joint surfaces. This result is 
consistant with many other experiments performed 
in our laboratory [14, 18, 19, 22]. It appeared that in 
this study, the development of osteophytes pre- 
ceded the development of carti lage lesions. There 
were no apparent differences in the gross 
pathology of DAR-treated arthrit ic joints com- 
pared with control arthrit ic joints. The contralat- 
eral control joints of all animals showed no signs 
of any pathological change. 
BLOOD B IOCHEMISTRY 
The following parameters were examined: glu- 
cose, protein (albumin and globulins), urea, 
creatin.ine, alkaline phosphatase, alanine transam- 
inase, aspartate transaminase, bilirubin, Na ÷, K ÷, 
Ca 2÷, P, CF and cholesterol. All values fell within 
normal ranges for the whole duration of the study. 
There was no difference between the DAR treated 
group and the control group at any time during the 
study. In addition, a full hematology screen was 
performed, again there were no significant differ- 
ences between the DAR treated and control ani- 
mals, and all values fell within the normal range. 
CLINICAL SIGNS 
There was no significant effect of the DAR 
treatment upon body-weight. As might be ex- 
pected, treatment with DAR also had no significant 
effect on food consumption over the test period. 
Colored urine and feces were observed in most 
animals for the duration of the study but was not 
clinically significant because the pink coloration 
was due to rhein (the major metabolite of DAR) 
which at slightly basic pH is intensely purple. At 
more acidic pH, rhein is yellow in color. The only 
detrimental side effects encountered in the DAR 
group was a mild diarrhea and an increased 
incidence of vomiting. All dogs experienced at 
least one episode of diarrhea, the minimum 
observed was one episode during the study and the 
maximum was 10 episodes per animal. The mean 
value was four episodes per animal during the test 
period. Only one animal in the control group, and 
three in the treated, had episodes of vomiting. The 
bulk of the observations (13/21) were due to a 
single animal, dog 982. The diarrhea was a known 
side effect of DAR administration i  humans [2] 
and was not unexpected, reports of vomiting were 
not, however, reported from human trials and may 
be of little consequence because the bulk of 
observations were from a single animal. 
PROTEOGLYCAN SYNTHESIS  
Table I shows the results of the incorporation of 
3~SO4 into proteoglycans from control and os- 
teoarthrit ic arti lage from joints obtained from 
DAR-dosed and non-dosed animals. It can be seen 
that DAR produces a significant reduction 
(P < 0.047) in the rate of synthesis of nonoperated 
control tissue from the medial tibial plateau only. 
It can be noted, however, that in all cases, the 
synthesis rates in the DAR-treated animals were 
all lower than non-DAR treated, although not 
significantly so. DAR also produced a significant 
reduction in the rate of synthesis of arthrit ic tissue 
from the lateral femoral condyle compared with 
arthrit ic tissue from non-treated animals. It was 
perhaps of interest hat only two anatomical sites 
in animals not dosed with DAR showed statisti- 
cally increased rates of synthesis in osteoarthrit ic 
compared with controls. These were the medial 
tibial plateau (P < 0.031) and the lateral femoral 
condyle (P < 0.031). 
PROTEOGLYCAN TURNOVER 
Table II shows the results of the effects of DAR 
on the turnover of proteoglycans (assessed as the 
release of labeled proteoglycans or their fragments 
into the maintenance medium during the chase 
period as a percentage of total radiolabeled 
proteoglycans). DAR had a significant effect on the 
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Table I 
Effect of diacetyl rhein (DAR) on the rate of incorporation of sulfate 
into proteoglycans from cartilage from control and experimental 
ostearthritic joints 
Non-DAR treated DAR treated 
Sulfate incorporation Sulfate incorporation 
(pmols/h/pg hydroxyproline) (pmols/h/~g hydroxyproline) 
Site Control Arthritic Control Arthritic 
MTP 0.90 ± 0.27 1.21 _+ 0.36t 0.73 ± 0.17" 0.78 ± 0.18 
LTP 0.83 ± 0.29 0.81 ± 0.24 0.68 ± 0.16 0.60 ± 0.23 
MFC 1.01 ± 0.78 1.16 ± 0.48 0.62 ± 0.21 1.10 ± 0.27:~ 
LFC 0.72 ± 0.19 1.02 _+ 0.34t 0.59 ± 0.26 0.71 ± 0.32* 
PG 0.74 ± 0.26 1.22 ± 0.92 0.56 _+ 0.28 0.63 ± 0.20 
The effect of DAR on the synthesis of proteoglycans from 
osteoarthritic and contralateral control joint cartilage. MTP 
refers to the medial tibial plateau; LTP refers to the lateral tibial 
plateau; MFC to the medial femoral condyle; LFC to the lateral 
femoral condyle and PG to the patella groove. The figures in the 
columns refer to the incorporation of sulfate in pmols SO4/h/~g 
hydroxyproline. The values show the mean _ 1 S.D. 
The figures marked * in the DAR-treated column indicate a 
statistically significant (P < 0.047) reduction in incorporation 
compared with the corresponding non-DAR treated column. 
Figures marked t indicate a statistically significant (P < 0.031) 
increase in arthritic values compared with corresponding controls. 
Figures marked :~ indicate a significant (P < 0.016) increase 
compared with corresponding DAR-treated controls. Significance 
was determined in all cases using a one-tailed Walsh test for paired 
data. 
reduct ion of tu rnover  in the femoral  condy lar  
compartments .  In this study, s igni f icant increases 
in the turnover  from arthr i t ic  compared  with 
control  was seen in only the latera l  t ibial  p la teau 
and media l  femoral  condyle which probab ly  
reflects a less-severe deve lopment  of the disease 
process in these animals.  We would suggest  that  
this may demonst ra te  our  or ig inal  premise that  
a l tered hous ing condi t ions may reduce the sever i ty  
of the disease. As was seen in the prev ious  sect ion 
on proteog lycan synthesis,  a l though DAR only 
produced signif icant reduct ions  in tu rnover  in 
osteoarthr i t ic  t issue from the femoral  
compartment ,  DAR reduced the values f rom all 
areas comparedwi th  the corresponding non-dosed 
tissue, whether  ar thr i t i c  or control.  
HYDROXYPROLINE CONCENTRATION 
Table  I I I  shows that  there was a highly 
signif icant decrease in the hydroxypro l ine  con- 
centrat ion  of ar thr i t ic  t issue compared  with 
controls.  Hydroxypro l ine  contents  were deter- 
mined after  culture.  Swel l ing of the osteoarthr i t i c  
t issue could account  for the signif icant reduct ion 
of hydroxypro l ine  in osteoarthr i t ic  t issue com- 
pared with cont ra la tera l  control  t issue. This is 
cons istent  with other  observat ions  wh ich  have  
demonst ra ted  an increase in hydrat ion  and an 
increased abi l i ty of osteoarthr i t i c  car t i lage  to 
swell. DAR is capable  of prevent ing  this  increase 
in both  the media l  and latera l  t ibial  p la teaux  and 
the pate l lar  groove. In these areas, there  was a 
stat is t ica l ly  s igni f icant increase in the concen- 
t rat ion  of hydroxypro l ine  in the DAR- t reated  
osteoar thr i t i c  t issue compared  with non- t reated  
ar thr i t ic  t issue. There  was no stat is t ica l  differ- 
ence between DAR-t reated contro l  and os- 
teoar thr i t i c  concent ra t ions  of hydroxypro l ine  at  
these sites, a l though there was a s igni f icant 
di f ference in the femoral  condyles. 
. . . .  GLYCOSAMINOGLYCAN CONCENTRATION 
There  were s igni f icant decreases in the concen- 
t ra t ion  of g lycosaminog lycan (GAG) per wet  
weight  of t issue f rom osteoarthr i t i c  compared  wi th  
contro l  cart i lage in non-DAR t reated  jo ints  
(Table IV), para l le l ing the f indings for hydroxypro-  
l ine shown in Table II I .  However ,  there was no 
s ignif icant dif ference in the values for non-DAR 
t reated  ar thr i t i c  t issue compared  wi th  DAR- 
t reated ar thr i t ic  tissue. This cont ras ted  with the 
data for hydroxypro l ine,  where both  t ibial  
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Table II 
Effect of diacetyl rhein (DAR) on the turnover of newly-synthesized 
proteoglycans from cartilage obtained from control and experimental 
ostearthritic joints 
Non-DAR treated DAR treated 
Proteoglycan turnover Proteoglycan turnover 
(% of total synthesized (% of total synthesized 
present in medium after 48 h) present in medium after 48 h) 
Site Control Arthritic Control Arthritic 
MTP 21.38 _+ 5.44 22.33 ± 4.83 16.35 ± 7.49 17.47 i 6.09 
LTP 19.08 ± 5.53 28.60 ± 12.6t 17.40 ± 10.2 17.00 i 8.38 
MFC 15.32 ± 8.16 20.02 ± 6.595 13.58 ± 6.29 13.17 ± 4.18"* 
LFC 18.82 ± 8.63 20.63 ± 7.41 13.75 ± 7.42 16.30 i 11~00" 
PG 16.27 ± 6.84 16.37 ± 7.69 13.37 + 5.85 13.65 ± 6.85 
The effect of DAR on proteoglycan turnover. Abbreviations are 
exactly as in Table I. The figures show the mean ± 1 S.D. Of the 
percentage of radio labeled proteoglycan i the chase medium as 
a proportion of total incorporation. 
Values marked * indicate a significant (P < 0.047) decrease in 
the DAR-treated osteoarthritic group compared with correspond- 
ing non DAR-treated osteoarthritic tissue and values marked ** 
indicate a similar change of higher significance (P < 0.031). The 
figures in the non-DAR treated arthritic column marked t and $ 
indicate a significant increase compared with non-DAR treated 
controls (P < 0.031 and 0.047, respectively). Significance was 
determined in all cases using a one-tailed Walsh test for paired 
data. " 
p lateaux and the patel lar groove showed signifi- 
cant ly higher values for the DAR treated arthr i t ic  
tissue than corresponding non-DAR treated 
arthr i t ic  tissue. With the exception of the DAR 
treated medial tibial p lateau (which was signifi- 
cant ly (P < 0.047) higher) and the patel lar groove 
(not signif icant statistically), the arthr i t ic  t issue 
showed signif icantly lower values than non-oper- 
ated control  tissue, as was  observed in the 
non-DAR treated group. The results for the 
hydroxyprol ine and,  g lycosaminoglycan concen- 
trat ions would suggest hat  a l though the decrease 
in concentrat ion of both species may be largely 
attr ibuted to an increase in the hydrat ion  or 
capacity of the arthr i t ic  cart i lage to swell, the 
reversal of the hydroxyprol ine trend by DAR may 
Table III 
Effect of diacetyl rhein (DAR) on the concentration ofhydroxyproline from cartilage of 








(pg/mg wet weight cartilage) 
Site Control Arthritic Control Arthritic 
MTP 12.82 ± 1.29"** 9.79 _ 1.59 13.63 ± 14.25 14.25 ± 2.40~t 
LTP 17.85 ± 6.04** 11.71 ± 1.24 17.94 ± 3.57 15.13 ± 4.85~ 
MFC 18.08 ± 1.95"** 12.68 ± 1.46 19.89 ± 7.28*** 14.66 ± 4.62 
LFC 22.79 ± 8.41"** 12.41 ± 1.66 22.73 ± 14.51"** 17.79 ± 10.44 
PG 1.9.97 ± 2.07*** 14.21 ± 2.66 22.00 ± 10.14 19.96 ± 8.94t 
The effect of DAR on the concentration of hydroxyproline as ~g/mg wet weight of 
cartilage. Abbreviations are exactly as in Table I. The values represent mean ± 1 S.D. 
Figures marked ***, ** indicate a statistically significant (P < 0.016, P < 0.031 
respectively) increase in the values for control tissue compared with corresponding 
arthritic values. Figures marked tt, t, indicate a statistically significant (P < 0.031, 
P < 0.047 respectively) increase in the DAR treated arthritic tissue compared with 
corresponding non-treated arthritic tissue. Significance was determined in all cases 
using a one-tailed Walsh test for paired data. 
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Table IV 
Effect of diacetyl rhein (DAR) on the concentration of glycosaminoglycan from cartilage 
of control and experimental ostearthritic joints 
Non-DAR treated 
Concentration of GAG 
(~g/mg wet weight cartilage) 
DAR treated 
Concentration of GAG 
(~tg/mg wet weight cartilage) 
Site Control Arthrit ic Control Arthrit ic 
MTP 75.47 _+ 18.07 62.73 i 17.12"** 68.89 i 13.02 73.45 i 18.81t 
LTP 100.79 i 31.71 67.14 _+ 27.25*** 100.69 i 6.20 61.57 i 12.64"** 
MFC 91.94 _+ 26.40 62.83 ± 9.21"** 101.22 i 19.90 74.75 i 7.42*** 
LFC 93.40 i 58.17 60.28 _+ 15.94"* 85.66 _+ 15.25 62.20 _+ 9.24*** 
PG 90.13 i 9.77 69.96 i 19.95"* 94.75 i 18.52 83.69 _+ 10.94 
The effect of DAR on the concentration of giycosaminoglycan s pg/mg wet weight 
of cartilage. Abbreviations are exactly as in Table I. Values represent mean i 1 S.D. 
Figures marked ***, ** indicate a statist ical ly significant (P < 0.016, P < 0.031 
respectively) decrease in the values for arthrit ic tissue compared with corresponding 
control values. Figures marked t indicate a statist ical ly significant (P < 0.047) increase 
in DAR treated arthrit ic tissue compared with DAR treated controls. Significance was 
determined in all cases using a one-tailed Walsh test for paired data. 
::not be solely due to a prevent ion  in swel l ing  and/or  
hydrat ion .  
CHONDROITIN 4- AND 6-SULFATION 
Table V shows that ,  as a resu l t  of induct ion  of 
os teoar thr i t i s ,  there  is an increase  in the pro- 
por t ion  of the 6-sul fated isomer of chondro i t in  
compared wi th  the 4-sulfate. This inc rease  is 
s ta t i s t i ca l ly  s ign i f icant  in al l  but  one (medial  
femoral  condyle)  of the areas  examined.  DAR 
produced ecreases in the propor t ion  of 6-sulfate in 
a r thr i t i c  t issue of al l  areas,  however  th is  was 
s ign i f i cant  only in the la tera l  femora l  condyle.  
DAR also produced reduct ions  in cont ro l  t i ssue in 
al l  a reas  examined,  however  this was s ign i f i cant  
only in the la tera l  t ib ia t  p la teau  and la tera l  femora l  
condyle.  It  is in teres t ing  also that  w i th  the 
except ion  of the media l  t ib ia l  p lateau,  there  was no 
s ign i f icant  d i f ference in the DAR- t reated  ar thr i t i c  
compared  wi th  the non-DAR- t reated  contro l ,  
whereas  as prev ious ly  ment ioned with one excep- 
t ion these were al l  s ign i f i cant  in the unt reated  
group. 
Table V 
Effect of diacetyl rhein (DAR) on the proportion of the 6-sulfated isomer of chondroitin 
sulfate as a percentage of the total sulfated disaccharides 
Non-DAR treated 
Chondroitin 6-sulfate 
(% of total chondroitin) 
DAR treated 
Chondroitin 6-sulfate 
(% of total chondroitin) 
Site Control Arthrit ic Control Arthrit ic 
MTP 66.10 ± 0.83 68.10 ± 2.19" 65.35 ± 2.48 67.87 _ 1.78t 
LTP 64.49 ± 2.61 66.40 ± 3.00** 61.84 ± 6.09§ 63.94 ± 2.555 
MFC 64.15 _ 2.22 67.72 ± 1.82 63.89 ± 3.81 64.26 ± 2.31 
LFC 64.14 ± 2.66 65.31 ± 2.73* ~. 61.73 ± 1.62§§ 64.23 ± 3.16 
PG 61.03 _+ 2.62 64.44 ± 3.69** 60.44 _+ 3.75 62.23 ± 3.27 
The effect of DAR on the proportion of the 6-sulfate isomer of chondroitin sulfate. 
Figures refer to the percent of total chondroitin. Values show mean i S.D. Figures 
marked **, * indicate a statistically significant (P < 0.031, P < 0.047, respectively) 
increase in non-treated arthrit ic tissue compared with non-treated control. Values 
marked $, indicate a statistically significant (P < 0.016) reduction in DAR treated 
arthrit ic tissue compared with non-treated arthrit ic tissue. Values marked §, §§ indicate 
a statistically significant (P < 0.016, P < 0.031, respectively) reduction in the DAR 
treated control compared with non-treated control tissue. Values marked t, indicate 
a statistically significant (P < 0.047) increase in DAR treated arthrit ic tissue compared 
with DAR treated control tissue. Significance was determined in all cases using a 
one-tailed Walsh test for paired data. 
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THE EFFECT OF DAR ON THE EXPRESSION OF 7-D-4 
EPITOPE IN NORMAL AND ARTHRITIC TISSUE 
Fig. 2(a) shows the effect of induct ion of 
test for paired data (one-tailed) it was shown that  
there was a signif icant (P < 0.047) increase in the 
staining of t issue sections with 7-D-4 in osteo- 
arthr i t ic  compared with contro l  tissue. A l though 
in general,  t reatment  with DAR seemed to increase 
staining in both arthr i t ic  and normal  t issue, the 
results were not signif icant. Fig. 2(b) shows the 
ef fect  of DAR on the expression of 7-D-4 in arthr i t ic  
tissue. There was no signif icant dif ference between 
the two groups. Final ly,  Fig. 2(c) shows the effect 
of DAR on the expression of 7-D-4 in contro l  
cart i lage. As before, there  was no s ignif icant 
dif ference between the two groups. 
Discuss ion  
DAR has an interest ing h istory in that  it was 
init ia l ly developed as a t reatment  for k idney stones 
by Charles Fr iedman, because when deacety lated 
to rhein, the molecule is capable of chelat ing metal  
ions, in par t icu lar  calc ium [27]. In this respect 
rhein shares st ructura l  similarit ies with other  
compounds that  can bind calcium, many of which 
are useful in the study of cart i lage and bone, for 
example, al izarin and tetracycl ine.  Quite serendip- 
itously, one of Fr iedman's  pat ients obta ined great  
rel ief  from his arthr i t is  as a result  of t reatment,  
and hence, the molecule was invest igated with 
some success for the t reatment  of osteoarthr i t is .  It
was claimed that  DAR behaved as an anti-inflam- 
matory analgesic. There  have been var ious 
publ icat ions upport ing this view [28, 29] but  quite 
c lear ly if rhein is behaving as an ant i - inf lammatory 
agent  it is showing an atypical  profi le because it is 
s lower in act ion than a standard NSAID (e.g. 
tenoxicam) [4] indicat ing that  perhaps its effect on 
FIG. 2. (a) The effect of the induction of osteoarthritis on 
the expression of the 7-D-4 epitope in tissue from the 
medial tibial plateau. The results were established by 
histological scoring by a method outlined in the text in 
the Materials and Methods section. (m), Normal; (~]), 
arthritic. (b) The effect of treatment with diacetyl rhein 
(20 mg/kg/day; 9 week study period) on the expression of 
7-D-4 epitope in osteoarthritic tissue from the medial 
tibial plateau. The results were obtained by histological 
examination of tissue sections as in Fig. 2(a). (m), 
Arthritic; (~]), arthritic (DAR treated). (c) The effect of 
diacetyl rhein (20 mg/kg/day; 9 week study period) on the 
expression of 7-D-4 epitope in normal (contralateral 
control) tissue from the medial tibial plateau. The 
results were obtained by histological examination of 
tissue sections as in Fig. 2(a). (m), Normal; (~3), normal 
(DAR treated). 
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pain may be due to the drug having a more 
fundamental, disease modifying effect. Moreover, 
it has been shown that DAR increases the 
synthesis of prostaglandins [29], which is in 
cont rast  with most NSAIDS although it must be 
stated that this would not be definitive evidence 
f;hat the molecule was not acting as an anti-inflam- 
matory agent. In support of the theory that DAR 
has a mode of action that is not related to its 
analgesic or anti-inflammatory properties, is that a 
very closely related entity, doxycycline, has been 
shown in animal models of osteoarthritis [30] to be 
effective in preventing disease progression. This 
may indicate that both act on a related mechanism 
because  they are chemically related, and doxycy- 
cline has not been reported to have any analgesic 
or anti-inflammatory action. 
It was thought hat DAR may have a novel mode 
of action that may be useful in the treatment of 
osteoarthritis. This study was intended to examine 
the effect of DAR upon the synthesis and turnover 
of proteoglycans in order that we might under- 
stand the mode of action of this drug in more detail 
in order to develop more effective, better tolerated 
anti-arthritic agents. 
In this study we noted a drug-induced iarrhea 
which could be attributed to the stimulation of 
prostaglandin synthesis [29], producing increased 
peristalsis because this effect can be inhibited in 
isolated guinea-pig ileum by treatment with 
indomethacin. Vomiting was another adverse 
reaction, however, this was infrequent and not 
noted in clinical trials in humans [4]. None of the 
other parameters examined (body weight, food 
consumption, blood biochemistry) showed any 
change from normal. A review of the literature, 
however, showed a more disturbing side effect hat 
is possessed by rhein and other related an- 
thraquinones. In various in vitro test systems, 
hydroxyanthraquinones have been shown to be 
tumour-promoting a ents, in particular hein has 
been demonstrated to exhibit weak clastogenic 
activity [30-34]. These properties seem to be 
related to the presence of free hydroxyl groups 
particularly in the 1, 8 position as in rhein [33]. It 
was for this reason that we abandoned our interest 
in DAR as an anti-osteoarthritic agent because the 
potential for tumour promotion in an elderly, 
chronically-dosed population was too great. 
However, it should be possible to prevent the 
clastogenic effects in rhein by substituting thc 
free hydroxyl groups with metabolically stable 
groups. 
DAR has been shown to be beneficial in the 
treatment of osteoarthritis in humans, but its mode 
of action is unclear. Although DAR has a rich and 
varied pharmacology, it was not clear whether any 
or all of the described properties of this compound 
were responsible for its disease modifying charac- 
teristics. Because synthesis and turnover are 
energy requiring processes it is entirely possible 
that restricting glucose to the chondrocyte may 
reduce both. In addition, the restriction of glucose 
may reduce the build up of lactic acid around the 
chondrocyte. Because cartilage is avascular, the 
removal of lactate is purely by diffusion. Should 
the chondrocyte become hypermetabolic, the 
increased levels of lactate produced may prove 
toxic to the cell because it has no mechanism for 
clearance per  se. Certainly DAR, and other 
anthraquinones of the DAR series, are capable of 
inhibiting glucose uptake (S.L. Carney, in prep- 
aration) and this property could be related to the 
ability of these compounds to inhibit turnover in 
an in vivo model of turnover in guinea-pigs [36]. 
Although in this study, statistical significance was 
not always reached, small differences may be 
biologically significant when one considers the 
length of duration of the arthritic disease in 
humans. It may also be that DAR may have more 
effect (see Tables I and II) on highly stimulated 
cells, and hence, would not achieve significance in 
this study since the degree of enhancement of 
synthesis and turnover were more moderate than 
one would normally aim to achieve with this 
model. 
Our intention in this study was to develop a mild 
osteoarthritis in these animals because we be- 
lieved that this would maximize our chances of 
demonstrating aneffect due to DAR. In retrospect, 
we should perhaps have tried to develop the most 
severe arthritis we could achieve because in this 
experiment we were unable to obtain the degree of 
difference in osteoarthritic artilage compared 
with controls that we would normally expect. This 
made interpretation of the differences due to drug 
treatment much more difficult. It has been my 
experience with this model that housing can 
significantly affect the natural history of the 
pathology. Animals that spend a lot of time on 
their hind legs (e.g. jumping up to see handlers and 
tSeir kennel mates) develop a more severe disease 
than those animals that do not spend a lot of time 
on their hind legs. This was the reason for 
choosing cages with low dividers in this study. 
Although one may be able to offer explanations 
for the behaviour of DAR at the molecular level in 
osteoarthritis, it is still difficult to rationalize this 
with the observed clinical benefit observed in 
human trials. Improvement based upon pain relief 
and functional indices indicated that DAR re- 
quired greater than 6 weeks treatment [1]. Such a 
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change however,  may suggest  that  as has been 
proposed, DAR works  not  on the in f lammatory  
component  of the disease, but  in fact  produces 
benefit  by a fundamenta l  change in cart i lage 
and bone metabol ism. Cer ta in  f indings of this 
and other  studies would suggest  that  this was 
the case. Most  conclusively,  there was a reversa l  
in the osteoarthr i t i s - induced change in the rat io  
of the sul fated d isacchar ide isomers of chon- 
droit in. Such changes in the rat io  of chondro i t in  
sul fate isomers has prev ious ly  been descr ibed in 
spontaneous ly  developing osteoar thr i t i s  in guinea- 
pigs [35]. 
I t  was not  possible to h isto logica l ly  demonst ra te  
that  DAR had an effect on the express ion of 7-D-4 
epitopes. I t  has been prev ious ly  Shown that  as a 
resul t  of induct ion of osteoarthr i t i s  there was a 
s ignif icant increase in the abundance  of these 
epitopes [18, 19]. This has been conf irmed by this 
study. The observat ion  that  there was no reduct ion 
in the epitope levels in DAR-treated animals  
and there may be a suggest ion that  DAR may 
even increase the levels, lends some support  to 
the idea that  7-D-4 express ion may reflect an 
a t tempted  repai r  process. It  may be that  DAR 
could enhance this natura l  process, and hence, 
have  its cl inical effect. To prove this it would be 
interest ing to examine the effects of DAR in models 
of repa i r  produced by in t ra -ar t icu lar  papa in  
in ject ion [37]. 
This study has shown that  a l though DAR can 
produce changes in cart i lage metabo l i sm and 
composi t ion in exper imenta l ly - induced osteoar-  
thr i t is  in the dog, such changes are small  in 
magn i tude  and reflect the except ion ra ther  than  
the rule. However,  some of the changes are of 
interest  and could po int  to potent ia l  long-term 
effects of the molecule.  Intui t ively,  one might  
assume that  the effects on turnover  and hydroxy- 
prol ine concent rat ion  may be in some way re lated 
to the beneficial  effect. I t  is possible, however,  that  
some other  aspect  of DAR pharmaco logy  may be 
responsib le for cl inical  improvement .  
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